News from sirnaomics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 14, 2021, 20:56 ET Sirnaomics Strengthens Its Development and Manufacturing Leadership with Promotions of Two Biopharma Veterans, Dr. Steven Long and Dr. Edward Wang

Sirnaomics, Inc., a biopharmaceutical company engaged in discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today...

Nov 16, 2021, 08:00 ET Sirnaomics to Present at TIDES Europe 2021

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Oct 18, 2021, 08:00 ET Sirnaomics to Present STP705, the Company's Lead Drug Candidate, for the Treatment of Cutaneous Squamous Cell Carcinoma in situ, at the 2021 Fall Clinical Dermatology Conference

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Sep 22, 2021, 09:00 ET Sirnaomics, Inc. to Present at TIDES USA 2021

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Jul 14, 2021, 10:00 ET Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Jul 06, 2021, 09:17 ET Sirnaomics Receives FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment

Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the company's IND...

Jul 01, 2021, 10:21 ET Sirnaomics Secures $105 Million in Series E Financing

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105...

Jun 30, 2021, 08:00 ET Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Jun 24, 2021, 08:00 ET Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Jun 16, 2021, 20:00 ET Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and...

Apr 29, 2021, 10:24 ET Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702

Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and...

Apr 25, 2021, 20:00 ET Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Apr 21, 2021, 20:00 ET Sirnaomics' Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development

RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today...

Feb 02, 2021, 11:33 ET Sirnaomics to Present at Medical Dermatology Summit

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Jan 17, 2021, 19:00 ET Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Dec 20, 2020, 18:00 ET Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Dec 03, 2020, 08:00 ET Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Oct 22, 2020, 21:16 ET Sirnaomics Seals US$105 Million Series D Financing to Fund Development of RNAi Therapeutics for Treatment of Cancers, Fibrotic Diseases and Viral Infections

Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed its...

Aug 25, 2020, 07:00 ET Sirnaomics Publishes Preclinical Study of Novel siRNA-Gemcitabine Conjugate for Advancing RNAi Therapeutics to Treat Multiple Types of Cancers

Sirnaomics, Inc. , a leading biopharmaceutical company in discovery and development of RNAi therapeutics for treatment of cancer and fibrotic...

Jun 11, 2020, 16:51 ET Sirnaomics Announces Decision to Spin off RNAimmune to Develop Novel mRNA Therapeutics and Vaccines

Sirnaomics, Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics, today announced a corporate...

Apr 08, 2020, 20:40 ET Sirnaomics Announces Positive Topline Results from Interim Analysis of Ongoing Phase II Clinical Trial Evaluating STP705 in Cutaneous Squamous Cell Carcinoma in situ (isSCC)

Sirnaomics Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic...

Mar 09, 2020, 10:00 ET Sirnaomics to Showcase Data for Lead Product STP705 in Human Squamous Carcinoma Tumor Model at 2020 American Academy of Dermatology Annual Meeting

Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Mar 04, 2020, 10:00 ET Sirnaomics to Present at 5th Annual Oligonucleotide & Precision Therapeutics Congress

Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Feb 10, 2020, 18:55 ET Sirnaomics' siRNA Therapeutic Candidate, STP705, Granted Orphan Drug Designation By US FDA for Treatment of Hepatocellular Carcinoma

Sirnaomics, Inc., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan...

Jan 24, 2020, 16:00 ET Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV

Sirnaomics Inc. ("Sirnaomics"), a leading biopharmaceutical company in discovery and development of novel RNAi therapeutics, announced today that it...